AR080892A2 - Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo - Google Patents

Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Info

Publication number
AR080892A2
AR080892A2 ARP110101253A ARP110101253A AR080892A2 AR 080892 A2 AR080892 A2 AR 080892A2 AR P110101253 A ARP110101253 A AR P110101253A AR P110101253 A ARP110101253 A AR P110101253A AR 080892 A2 AR080892 A2 AR 080892A2
Authority
AR
Argentina
Prior art keywords
complex
water insoluble
prepare
acetate
phthalate
Prior art date
Application number
ARP110101253A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080892(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR080892A2 publication Critical patent/AR080892A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un complejo insoluble en agua que comprende un compuesto estable a la humedad y al calor, amorfo seleccionado a partir del grupo formado por saquinavir y un polímero ionico insoluble en agua que tiene un peso molecular mayor que 80.000 D, una temperatura de transicion vítrea igual o mayor que 50sC, y está seleccionado a partir del grupo formado por poliacrilato, quitosan, polímeros carboxivinílicos, ftalato acetato de polivinilo, ftalato acetato de celulosa, policianoacrilatos, ftalato de hidroxipropilmetilcelulosa, tereftalato acetato de celulosa, succinato acetato de hidroxipropilmetilcelulosa, carboximetilcelulosa e hidroxipropilcelulosa de baja sustitucion, o una mezcla de dos o más de los polímeros ionicos anteriormente descriptos, en donde el compuesto terapéuticamente activo, estable amorfo está incorporado en el complejo compuesto/polímero predominantemente en forma amorfa, de acuerdo a lo determinado por difraccion de rayos X de polvo, y está presente en el complejo insoluble en agua en no menos del 10%, en peso, y el polímero ionico está presente en el complejo en no menos del 20%, en peso. También se dan a conocer: una composicion farmacéutica que comprende dicho complejo, métodos para preparar dicha composicion, método para preparar dicho complejo y un método para estabilizar un compuesto amorfo.
ARP110101253A 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo AR080892A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
AR080892A2 true AR080892A2 (es) 2012-05-16

Family

ID=26798138

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990104725A AR022096A1 (es) 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles
ARP110101253A AR080892A2 (es) 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990104725A AR022096A1 (es) 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles

Country Status (32)

Country Link
US (1) US6350786B1 (es)
EP (1) EP0988863B2 (es)
JP (5) JP2000095708A (es)
KR (1) KR100362019B1 (es)
CN (1) CN1201821C (es)
AR (2) AR022096A1 (es)
AT (1) ATE265232T1 (es)
AU (1) AU770745B2 (es)
BR (1) BR9904283A (es)
CA (1) CA2282906C (es)
CO (1) CO5140077A1 (es)
CZ (1) CZ300215B6 (es)
DE (1) DE69916733T3 (es)
DK (1) DK0988863T4 (es)
ES (1) ES2218918T5 (es)
HR (1) HRP990287B1 (es)
HU (1) HU228341B1 (es)
ID (1) ID24034A (es)
IL (1) IL131957A (es)
MA (1) MA26692A1 (es)
MY (1) MY124377A (es)
NO (1) NO326928B1 (es)
NZ (1) NZ337884A (es)
PE (1) PE20001049A1 (es)
PL (1) PL202757B1 (es)
PT (1) PT988863E (es)
RS (1) RS50193B (es)
RU (1) RU2240827C2 (es)
SG (1) SG97131A1 (es)
SI (1) SI0988863T2 (es)
TR (1) TR199902324A3 (es)
TW (1) TWI234465B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
PE20010659A1 (es) * 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
DE60117251T2 (de) * 2000-05-16 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Verfahren zur beschichtung von medizinischen geräten unter verwendung von superkritischem kohlendioxid
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) * 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
PT1401404E (pt) * 2001-05-30 2008-07-23 Csir Método de encapsular uma substância activa
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
CA2450762A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CN1681479A (zh) 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
CN100563658C (zh) * 2003-11-14 2009-12-02 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
EP1683525B1 (en) * 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
CA2561660C (en) * 2004-04-01 2012-10-30 Universite De Liege Pharmaceutical compositions of pyrimidine-2,4,6-triones
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
CN101115469A (zh) * 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
MX2007007919A (es) * 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
AU2006209239A1 (en) * 2005-01-27 2006-08-03 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrophilic biocompatible adhesive formulations and uses
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
US20080274192A1 (en) * 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008081829A1 (ja) 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2009052391A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
CA2738573C (en) * 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
WO2011152297A1 (ja) * 2010-05-31 2011-12-08 アステラス製薬株式会社 トリアゾール化合物の固体分散体
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
LT3135656T (lt) 2011-06-20 2019-04-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
IN2014CN02290A (es) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
KR102000312B1 (ko) * 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
RS57140B1 (sr) * 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
AU2013346501B2 (en) 2012-11-19 2017-07-13 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of CETP inhibitors
US10195150B2 (en) 2012-12-20 2019-02-05 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
US20160213575A1 (en) * 2013-09-11 2016-07-28 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
CA2928772A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
CA2987517A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
SI3447056T1 (sl) * 2016-12-13 2025-10-30 Transthera Sciences (Nanjing), Inc. Spojina, ki zavira multikinaze in njena kristalna oblika ter njena uporaba
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
CN113056457B (zh) 2018-12-03 2025-06-20 H.隆德贝克有限公司 用于治疗cns疾病的前药
TWI849043B (zh) 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
IL294928A (en) 2020-01-24 2022-09-01 Nanocopoeia Llc Amorphous solid dispersions of dasatinib and uses thereof
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
DK569786A (da) * 1985-11-27 1987-05-28 Syntex Inc Benzimidazolderivater
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2111065T5 (es) † 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
WO1997004782A1 (en) * 1995-07-26 1997-02-13 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion or solid dispersion preparation of xanthine derivatives
EP0952770A4 (en) † 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
PT1064279E (pt) 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular

Also Published As

Publication number Publication date
TR199902324A2 (xx) 2000-04-21
SI0988863T2 (sl) 2009-08-31
JP2000095708A (ja) 2000-04-04
HU228341B1 (en) 2013-03-28
HUP9903189A2 (hu) 2000-06-28
HRP990287A2 (en) 2000-06-30
JP2015187170A (ja) 2015-10-29
NZ337884A (en) 2001-02-23
NO326928B1 (no) 2009-03-16
CZ330499A3 (cs) 2000-04-12
CN1201821C (zh) 2005-05-18
JP6534979B2 (ja) 2019-06-26
JP2013035875A (ja) 2013-02-21
NO994583L (no) 2000-03-23
TWI234465B (en) 2005-06-21
IL131957A (en) 2005-06-19
MA26692A1 (fr) 2004-12-20
RS50193B (sr) 2009-05-06
KR20000023426A (ko) 2000-04-25
JP2016196515A (ja) 2016-11-24
HK1026632A1 (en) 2000-12-22
EP0988863B1 (en) 2004-04-28
BR9904283A (pt) 2000-09-26
ES2218918T3 (es) 2004-11-16
US6350786B1 (en) 2002-02-26
CN1251312A (zh) 2000-04-26
SI0988863T1 (en) 2004-08-31
IL131957A0 (en) 2001-03-19
PL202757B1 (pl) 2009-07-31
MY124377A (en) 2006-06-30
CO5140077A1 (es) 2002-03-22
DK0988863T4 (da) 2009-06-08
DK0988863T3 (da) 2004-08-30
RU2240827C2 (ru) 2004-11-27
AR022096A1 (es) 2002-09-04
ID24034A (id) 2000-07-06
JP6253135B2 (ja) 2017-12-27
NO994583D0 (no) 1999-09-21
CZ300215B6 (cs) 2009-03-18
DE69916733D1 (de) 2004-06-03
KR100362019B1 (ko) 2002-11-23
DE69916733T2 (de) 2005-03-31
HRP990287B1 (en) 2004-12-31
CA2282906C (en) 2010-07-20
DE69916733T3 (de) 2009-09-24
PE20001049A1 (es) 2000-10-17
YU47399A (es) 2002-08-12
AU4880799A (en) 2000-03-23
JP2007224048A (ja) 2007-09-06
ATE265232T1 (de) 2004-05-15
EP0988863A3 (en) 2000-08-09
PT988863E (pt) 2004-07-30
HUP9903189A3 (en) 2009-07-28
ES2218918T5 (es) 2009-06-23
AU770745B2 (en) 2004-03-04
CA2282906A1 (en) 2000-03-22
TR199902324A3 (tr) 2000-04-21
EP0988863A2 (en) 2000-03-29
SG97131A1 (en) 2003-07-18
PL335592A1 (en) 2000-03-27
HU9903189D0 (en) 1999-11-29
EP0988863B2 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
Bi et al. Temperature responsive self-assembled hydroxybutyl chitosan nanohydrogel based on homogeneous reaction for smart window
AU2001278471B2 (en) Stable salts of o-acetylsalicyclic with basic amino acids
AR011332A1 (es) Composicion que presenta propiedades de barrera a gases mejorada.
CA2278759A1 (en) Process for preparing synthetic soil-extract materials and medicaments based thereon
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
DK153948B (da) Analogifremgangsmaade til fremstilling af vandoploeselige associationsprodukter af (+)-katekin med en aminosyre og eventuelt tillige en anden syre
NO20022591L (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
ES2202069T3 (es) Procedimiento para la preparacion de una forma de dosificacion oral biodisponible de axetil cefuroxima.
ES8103027A1 (es) Un procedimiento para la preparacion de un polipeptido
EP0374888A3 (en) Sulfated tannins and theirs salts
ES2238703T3 (es) Alquilaciones selectivas de ciclodextrinas en los niveles de basicidad minima efectiva.
HUE025573T2 (en) Process for s-nitrosoglutation and the preparation of the process
ITMI20100365A1 (it) Silil- derivati di polisaccaridi
IL41902A (en) Immunogenic substance,its production,vaccine preparations containing it and their preparation
JPH064679B2 (ja) 粉末状絹フイブロインペプチド及びその製造法
CA2645574A1 (en) A medicine used for curing hyperphosphatemia and its preparation method
CN114853595B (zh) 一种丙戊酸钠、丙戊酸共晶的制备方法及其产品
CA1232275A (en) Photostabilisation of molsidomine
BRPI0013686B8 (pt) procedimento para sintetizar uma mistura de oligossacarídeos
ITFI980104A1 (it) Composizioni stabilizzate contenenti acido ialuronico,loro preparazione ed uso
Rattie et al. Acetaminophen prodrugs III: Hydrolysis of carbonate and carboxylic acid esters in aqueous buffers
KR930001909A (ko) 옥타데실-[2-(n-메틸피페리디노)-에틸]-포스페이트 및 이의 제조방법
CN114762736A (zh) 一种离子液体改性壳聚糖水凝胶及其制备方法和应用
JPS54120696A (en) Glucosamine derivative and its preparation
JPH03170435A (ja) ウイルス疾患の治療および予防用高分子電解質複合体

Legal Events

Date Code Title Description
FC Refusal